NASDAQ:BCYC - Bicycle Therapeutics Stock Price, News, & Analysis

$14.57
+1.33 (+10.05 %)
(As of 06/19/2019 03:03 AM ET)
Today's Range
$13.3338
Now: $14.57
$14.8975
50-Day Range N/A
52-Week Range
$10.60
Now: $14.57
$14.91
Volume152,701 shs
Average Volume94,384 shs
Market Capitalization$257.83 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Bicycle Therapeutics Limited, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in preclinical studies targeting EphA2; BT8009, which is in preclinical studies targeting Nectin-4; and CD137, an immune cell co-stimulatory molecule that is in preclinical stage, as well as systemically-delivered activators. In addition, it is developing THR-149, a key immune cell co-stimulatory molecule that is in Phase I clinical trials. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, hematology, ophthalmology, and respiratory indications. The company has a clinical trial and license agreement with the Cancer Research Technology Limited and CRUK; and research collaboration agreement with Bioverativ Inc., AstraZeneca AB, and Oxurion NV. The company was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BCYC
CUSIPN/A
CIKN/A
Phone44-12-2349-7415

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees61
Market Cap$257.83 million
Next Earnings DateN/A
OptionableNot Optionable

Receive BCYC News and Ratings via Email

Sign-up to receive the latest news and ratings for BCYC and its competitors with MarketBeat's FREE daily newsletter.

Bicycle Therapeutics (NASDAQ:BCYC) Frequently Asked Questions

What is Bicycle Therapeutics' stock symbol?

Bicycle Therapeutics trades on the NASDAQ under the ticker symbol "BCYC."

What price target have analysts set for BCYC?

4 analysts have issued twelve-month price objectives for Bicycle Therapeutics' shares. Their predictions range from $20.00 to $22.00. On average, they expect Bicycle Therapeutics' stock price to reach $21.3333 in the next year. This suggests a possible upside of 46.4% from the stock's current price. View Analyst Price Targets for Bicycle Therapeutics.

What is the consensus analysts' recommendation for Bicycle Therapeutics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bicycle Therapeutics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Bicycle Therapeutics.

Has Bicycle Therapeutics been receiving favorable news coverage?

News coverage about BCYC stock has been trending somewhat positive on Wednesday, InfoTrie Sentiment Analysis reports. InfoTrie ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Bicycle Therapeutics earned a media sentiment score of 1.6 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the immediate future. View News Stories for Bicycle Therapeutics.

Who are some of Bicycle Therapeutics' key competitors?

What other stocks do shareholders of Bicycle Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bicycle Therapeutics investors own include Canopy Growth (CGC), Cronos Group (CRON), Applied Materials (AMAT), Array Biopharma (ARRY), FOX (FOX), Hain Celestial Group (HAIN), Restoration Robotics (HAIR), Intra-Cellular Therapies (ITCI), The Medicines (MDCO) and Micron Technology (MU).

Who are Bicycle Therapeutics' key executives?

Bicycle Therapeutics' management team includes the folowing people:
  • Dr. Kevin Lee M.B.A., Ph.D., CEO & Director (Age 51)
  • Mr. Lee H. Kalowski, Pres & CFO (Age 38)
  • Mr. Christian Heinis, Scientific Founder
  • Sir Gregory Winter, Co-Founder, Director & Member of Scientific Advisory Board (Age 68)
  • Mr. Michael Skynner, Chief Operating Officer (Age 50)

When did Bicycle Therapeutics IPO?

(BCYC) raised $64 million in an initial public offering (IPO) on Thursday, May 23rd 2019. The company issued 4,300,000 shares at $14.00-$16.00 per share. Goldman Sachs, Jefferies and Piper Jaffray acted as the underwriters for the IPO and Canaccord Genuity was co-manager.

When does Bicycle Therapeutics' quiet period expire?

Bicycle Therapeutics' quiet period expires on Tuesday, July 2nd. Bicycle Therapeutics had issued 4,333,333 shares in its IPO on May 23rd. The total size of the offering was $60,666,662 based on an initial share price of $14.00. During Bicycle Therapeutics' quiet period, insiders and any underwriters involved in the IPO are prevented from issuing any earnings forecasts or research reports for the company because of SEC regulations. Following the expiration of the company's quiet period, it's expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

How do I buy shares of Bicycle Therapeutics?

Shares of BCYC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Bicycle Therapeutics' stock price today?

One share of BCYC stock can currently be purchased for approximately $14.57.

How big of a company is Bicycle Therapeutics?

Bicycle Therapeutics has a market capitalization of $257.83 million. Bicycle Therapeutics employs 61 workers across the globe.View Additional Information About Bicycle Therapeutics.

What is Bicycle Therapeutics' official website?

The official website for Bicycle Therapeutics is http://www.bicycletherapeutics.com/.

How can I contact Bicycle Therapeutics?

Bicycle Therapeutics' mailing address is B900 BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0, CB22 3AT. The company can be reached via phone at 44-12-2349-7415.


MarketBeat Community Rating for Bicycle Therapeutics (NASDAQ BCYC)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  5 (Vote Outperform)
Underperform Votes:  3 (Vote Underperform)
Total Votes:  8
MarketBeat's community ratings are surveys of what our community members think about Bicycle Therapeutics and other stocks. Vote "Outperform" if you believe BCYC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BCYC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/19/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel